BioSpace News Archive

Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma Bright” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a letter of intent (“LOI”) with AI4LYF LLC (“AI4LYF”) for the exclusive licensing rights for a digital cough-based diagnosis screening technology.

MiNK Therapeutics, Inc. announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday December 1st, at 4:45 PM ET.

Sermonix Pharmaceuticals Inc. today announced that it had four abstracts accepted as poster presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 6-10 at the Henry B. Gonzalez Convention Center in San Antonio.

At the 21st Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in Orlando, SPR Therapeutics is highlighting five new data sets demonstrating significant pain relief for a majority of patients resulting from 60-day PNS treatment using the SPRINT® PNS System.

CurePSP has announced the designation of Queen’s Parkinson’s and Movement Disorders Center in Hawaii and the Department of Neurology at the University of Michigan as CurePSP Centers of Care, bringing the total to 30 centers across the United States and Canada.

Pathnostics announced the broadening of its diagnostic laboratory capabilities with the opening of its third lab, located in Lake Mary, Florida, and expansion of its Irvine, California-based laboratory and headquarters.

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.

Vicarious Surgical Inc. announced that renowned surgeon Igor Belyansky, MD, used the Vicarious Surgical Beta 2 prototype, to successfully perform two cadaveric ventral hernia repair procedures.